These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
243 related articles for article (PubMed ID: 37264314)
1. An N6-methyladenosine regulation- and mRNAsi-related prognostic index reveals the distinct immune microenvironment and immunotherapy responses in lower-grade glioma. Tang G; Peng J; Huo L; Yin W BMC Bioinformatics; 2023 Jun; 24(1):225. PubMed ID: 37264314 [TBL] [Abstract][Full Text] [Related]
2. The prognostic value and immune landscaps of m6A/m5C-related lncRNAs signature in the low grade glioma. Li R; Chen H; Li C; Qi Y; Zhao K; Wang J; You C; Huang H BMC Bioinformatics; 2023 Jul; 24(1):274. PubMed ID: 37403043 [TBL] [Abstract][Full Text] [Related]
3. N6-methyladenosine RNA methylation regulator-related alternative splicing gene signature as prognostic predictor and in immune microenvironment characterization of patients with low-grade glioma. Maimaiti A; Tuersunniyazi A; Meng X; Pei Y; Ji W; Feng Z; Jiang L; Wang Z; Kasimu M; Wang Y; Shi X Front Genet; 2022; 13():872186. PubMed ID: 35937991 [No Abstract] [Full Text] [Related]
4. Comprehensive analysis of tumor immune microenvironment and prognosis of m6A-related lncRNAs in gastric cancer. Wang Y; Zhu GQ; Tian D; Zhou CW; Li N; Feng Y; Zeng MS BMC Cancer; 2022 Mar; 22(1):316. PubMed ID: 35331183 [TBL] [Abstract][Full Text] [Related]
5. Exploring the prognostic potential of m6A methylation regulators in low-grade glioma: implications for tumor microenvironment modulation. Wu H; Chen S; Hu Z; Ge R; Ma L; You C; Huang Y Eur J Med Res; 2024 Jan; 29(1):19. PubMed ID: 38173044 [TBL] [Abstract][Full Text] [Related]
6. Recurrence- and Malignant Progression-Associated Biomarkers in Low-Grade Gliomas and Their Roles in Immunotherapy. Teng C; Zhu Y; Li Y; Dai L; Pan Z; Wanggou S; Li X Front Immunol; 2022; 13():899710. PubMed ID: 35677036 [TBL] [Abstract][Full Text] [Related]
7. Integrated analysis of inflammatory response subtype-related signature to predict clinical outcomes, immune status and drug targets in lower-grade glioma. Cao Y; Zhu H; Chen Q; Huang H; Xie D; Li X; Jiang X; Ren C; Peng J Front Pharmacol; 2022; 13():914667. PubMed ID: 36091778 [No Abstract] [Full Text] [Related]
8. Comprehensive analyses indicated the association between m6A related long non-coding RNAs and various pathways in glioma. Chen Z; Zhang W; Yan Z; Zhang M Cancer Med; 2023 Jan; 12(1):760-788. PubMed ID: 35668574 [TBL] [Abstract][Full Text] [Related]
9. Integrating m6A Regulators-Mediated Methylation Modification Models and Tumor Immune Microenvironment Characterization in Caucasian and Chinese Low-Grade Gliomas. Liu W; Li C; Wu Y; Xu W; Chen S; Zhang H; Huang H; Zhao S; Wang J Front Cell Dev Biol; 2021; 9():725764. PubMed ID: 34900988 [No Abstract] [Full Text] [Related]
10. Use of Novel m6A Regulator-mediated Methylation Modification Patterns in Distinct Tumor Microenvironment Profiles to Identify and Predict Glioma Prognosis and Progression, T-cell Dysfunction, and Clinical Response to ICI Immunotherapy. Zhao B; Xiang Z; Wu B; Zhang X; Feng N; Wei Y; Zhang W Curr Pharm Des; 2023; 29(1):60-78. PubMed ID: 36503445 [TBL] [Abstract][Full Text] [Related]
11. Immunological Value of Prognostic Signature Based on Cancer Stem Cell Characteristics in Hepatocellular Carcinoma. Xu Q; Xu H; Chen S; Huang W Front Cell Dev Biol; 2021; 9():710207. PubMed ID: 34409040 [No Abstract] [Full Text] [Related]
12. Prognostic Value of a Stemness Index-Associated Signature in Primary Lower-Grade Glioma. Zhang M; Wang X; Chen X; Guo F; Hong J Front Genet; 2020; 11():441. PubMed ID: 32431729 [TBL] [Abstract][Full Text] [Related]
13. Integrative Analysis of Neuregulin Family Members-Related Tumor Microenvironment for Predicting the Prognosis in Gliomas. Zhao WJ; Ou GY; Lin WW Front Immunol; 2021; 12():682415. PubMed ID: 34054873 [TBL] [Abstract][Full Text] [Related]
14. Identification and verification of the ferroptosis- and pyroptosis-associated prognostic signature for low-grade glioma. Wang J; Ren J; Liu J; Zhang L; Yuan Q; Dong B Bosn J Basic Med Sci; 2022 Sep; 22(5):728-750. PubMed ID: 35276059 [TBL] [Abstract][Full Text] [Related]
15. Analysis of N6-methyladenosine-related lncRNAs in the tumor immune microenvironment and their prognostic role in pancreatic cancer. Liu Y; Wang T; Fang Z; Kong J; Liu J J Cancer Res Clin Oncol; 2022 Jul; 148(7):1613-1626. PubMed ID: 35314871 [TBL] [Abstract][Full Text] [Related]
16. Association of RNA-modification "writer" genes with prognosis and response to immunotherapy in patients with low-grade glioma. Zhang L; Qu C; Shi C; Wu F; Tang Y; Li Y; Li J; Feng H; Zhong S; Yang J; Zeng X; Peng X PLoS One; 2023; 18(1):e0279119. PubMed ID: 36649311 [TBL] [Abstract][Full Text] [Related]
17. Analysis of m6A-Related Signatures in the Tumor Immune Microenvironment and Identification of Clinical Prognostic Regulators in Adrenocortical Carcinoma. Jin Y; Wang Z; He D; Zhu Y; Hu X; Gong L; Xiao M; Chen X; Cheng Y; Cao K Front Immunol; 2021; 12():637933. PubMed ID: 33746977 [TBL] [Abstract][Full Text] [Related]
18. m6A Regulators Mediated Methylation Modification Patterns and Tumor Microenvironment Infiltration Characterization In Nasopharyngeal Carcinoma. Liu Z; He J; Han J; Yang J; Liao W; Chen N Front Immunol; 2021; 12():762243. PubMed ID: 35069534 [TBL] [Abstract][Full Text] [Related]
19. An effective N6-methyladenosine-related long non-coding RNA prognostic signature for predicting the prognosis of patients with bladder cancer. Ma T; Wang X; Meng L; Liu X; Wang J; Zhang W; Tian Z; Zhang Y BMC Cancer; 2021 Nov; 21(1):1256. PubMed ID: 34802433 [TBL] [Abstract][Full Text] [Related]
20. Integrative Analysis of Biomarkers Through Machine Learning Identifies Stemness Features in Colorectal Cancer. Wei R; Quan J; Li S; Liu H; Guan X; Jiang Z; Wang X Front Cell Dev Biol; 2021; 9():724860. PubMed ID: 34568334 [No Abstract] [Full Text] [Related] [Next] [New Search]